Spasmodic dysphonia (SD), now more precisely termed laryngeal dystonia, is a task-specific focal neurological disorder in which involuntary, sustained spasms of the intrinsic muscles of the larynx occur selectively during phonation (voice production), causing abnormal, effortful, or interrupted voice quality. Unlike structural vocal cord disorders (e.g., polyps, paralysis), spasmodic dysphonia is fundamentally a neurological movement disorder — a form of focal dystonia originating from dysfunction in the basal ganglia and its connections, producing abnormal motor neuron signaling to the laryngeal musculature during speech. The condition is classified into three primary types based on which muscle group is affected: Adductor spasmodic dysphonia (ADSD) — by far the most common (~87% of cases) — involves spasms of the vocal cord-closing muscles (thyroarytenoid, lateral cricoarytenoid, interarytenoid), producing a strained, strangled, or choked voice quality with involuntary voice breaks during vowel sounds. Abductor spasmodic dysphonia (ABSD) involves spasms of the vocal cord-opening muscles (posterior cricoarytenoid), producing a breathy, whispery, or aspirate voice with prolonged voiceless segments. Mixed spasmodic dysphonia involves elements of both. Critically, all three types are task-specific to speech — symptoms are typically absent or markedly reduced during whispering, singing, laughing, crying, or yawning, which are key clinical differentiators used during laryngoscopic examination to confirm the diagnosis. The condition predominantly affects women aged 40-60, is generally lifelong with no cure, but responds well to periodic botulinum toxin chemodenervation of the affected laryngeal muscles, which remains the gold-standard treatment. In ICD-10-CM, spasmodic dysphonia is coded as R49.0 (Dysphonia), as there is no dedicated spasmodic-dysphonia-specific code, though when documented explicitly as laryngeal dystonia, the code G24.8 (Other dystonia) may be supported.
Greek σπασμός (spasmós), from σπάω (spáō), “to pull, tear, wrench"
"Spasm, convulsion, involuntary contraction” — denoting the sudden, involuntary muscle pulling characteristic of the disorder; also underlying spasm, spastic
Literally: “difficult or abnormal spasm-like voice” — compound of Greek spasmōdēs (“convulsive”) + dysphōniā (“roughness or difficulty of sound/voice”). The term dysphonia entered New Latin and English in the 1700-10 period, from Greek dysphōniā, meaning “roughness of sound” (dys- + phōnē). Spasmodic dysphonia as a clinical entity was first formally described by Traube in 1871, who called it spastische Dysphonie (spastic dysphonia). The term laryngeal dystonia has been preferred since the 1980s-1990s as the neurological mechanism became better understood, but spasmodic dysphonia remains the dominant clinical and coding term in current US practice. The suffix -phonia is also seen in aphonia (complete loss of voice), dysphonia (impaired voice), euphonia (pleasant voice), and hypophonia (reduced vocal volume as in Parkinson disease).
🔀 ALIASES / ALTERNATE TERMS
Term
Context
Laryngeal dystonia
Neurologically precise preferred term; emphasizes basal ganglia origin; increasingly favored in academic/movement disorder literature
Adductor spasmodic dysphonia (ADSD)
Most common subtype (~87%); strained-strangled voice; thyroarytenoid + lateral cricoarytenoid spasm; treated with bilateral thyroarytenoid Botox
Abductor spasmodic dysphonia (ABSD)
Less common (~13%); breathy, whispery voice; posterior cricoarytenoid spasm; treated with posterior cricoarytenoid Botox
Mixed spasmodic dysphonia
Both adductor and abductor muscle involvement; most difficult subtype to treat
Spastic dysphonia
Older historical term (Traube, 1871); no longer preferred but occasionally seen in older documentation
Dysphonia spastica
Latin form; used in older European medical literature
Task-specific laryngeal dystonia
Emphasizes the phonation-specificity of the spasms; distinguishes SD from other movement disorders
Focal voice dystonia
Classifies SD within the dystonia spectrum; emphasizes the circumscribed, organ-specific nature
Aphonia
Extreme end of the spectrum; complete loss of voice; seen in severe or undertreated SD
Muscle tension dysphonia (MTD)
Key differential diagnosis; functional voice disorder with laryngeal hyperfunction but not neurological; coded R49.0 — may coexist with SD
Vocal tremor
May coexist with SD; involves rhythmic oscillation of the vocal cords; may require separate coding and treatment approach
🔗 RELATED TERMS
Focal dystonia — the neurological category to which SD belongs; task-specific, body-region-limited movement disorder; SD is one of many focal dystonias (e.g., blepharospasm, cervical dystonia)
Basal ganglia — the deep brain structure implicated as the origin of aberrant motor signaling in SD; same region implicated in Parkinson disease and other movement disorders
Chemodenervation — the pharmacological mechanism of Botox treatment; temporary muscle-weakening via acetylcholine blockade at the neuromuscular junction
Dysphonia — the umbrella symptom and ICD-10-CM code for spasmodic dysphonia; R49.0; also coded for all other forms of impaired voice
aphonia — complete loss of voice; coded R49.1; the extreme end of the SD severity spectrum
vocal cord paralysis — J38.01 / J38.02; structurally distinct from SD but often confused clinically; key differential: VCP is flaccid/fixed; SD cords are mobile with spasms
Muscle tension dysphonia (MTD) — functional hypertonicity without neurological origin; must be ruled out before SD diagnosis; also coded R49.0
Laryngoscopy / Videostroboscopy — essential diagnostic tool; reveals task-specific vocal cord spasms during phonation but not during whispering, coughing, or laughing
Laryngeal EMG — electromyography of the laryngeal muscles; used to guide Botox injection placement and to differentiate SD from VCP; CPT 95865
Blepharospasm — G24.5; focal dystonia of the eyelid; another related focal dystonia; may co-occur with SD in Meige syndrome
Essential tremor of voice — rhythmic voice oscillation distinct from SD; can coexist; classified under G25.0
Voice therapy — adjunct treatment; less effective as monotherapy for SD than for MTD; CPT 92507; used to maximize Botox outcomes
Phonosurgery — surgical options for SD refractory to Botox; selective laryngeal adductor denervation-reinnervation (SLAD-R); not widely adopted
Recurrent laryngeal nerve (RLN) — the peripheral nerve targeted by chemodenervation; motor supply to thyroarytenoid and posterior cricoarytenoid muscles
CODING CORNER
🏥 ICD-10-CM CODES
Primary Diagnosis — Spasmodic Dysphonia
⚠️ ICD-10-CM does not have a dedicated “spasmodic dysphonia” code. Code selection depends on how the physician documents the condition — as a voice/symptom-level diagnosis or as a neurological dystonia.
Dysphonia(the primary and most commonly used code for spasmodic dysphonia in outpatient/ENT settings; includes hoarseness; used when documented as “spasmodic dysphonia” without explicit dystonia classification)
Laryngoscopy, flexible or rigid telescopic, with stroboscopy (videostroboscopy; gold-standard visualization of vocal fold vibration pattern during phonation)
Chemodenervation of muscle(s); larynx, unilateral, percutaneous (e.g., for spasmodic dysphonia), includes guidance by needle electromyography, when performed (primary CPT code for percutaneous Botox injection for SD; EMG guidance is included — do NOT separately report +95874 with 64617)
Chemodenervation — Via Laryngoscopy (Direct Approach)
Laryngoscopy, direct, with injection into vocal cord(s), therapeutic (direct laryngoscopy approach to Botox injection; OR-based; used when percutaneous approach is not feasible)
Laryngoscopy, direct, operative, with injection into vocal cord(s), therapeutic; with operating microscope or telescope (direct approach with optical magnification; typically general anesthesia)
Laryngoscopy, flexible, diagnostic with therapeutic injection(s) (e.g., chemodenervation agent or corticosteroid); unilateral (flexible scope therapeutic injection; office-based; does NOT include EMG guidance — add +95874 separately if EMG guidance used)
Needle electromyography for guidance in conjunction with chemodenervation (add-on code; list separately; use ONLY with 31573, 31570, 31571, or other applicable primary codes — NOT with 64617, which already includes EMG guidance)
Bilateral procedure — 64617 is a unilateral code; append -50 when bilateral Botox is injected (e.g., both thyroarytenoid muscles in ADSD); CMS confirms bilateral modifier applies to 64617
Professional component — append to 95874 (EMG guidance) when the physician does not own the EMG equipment (facility owns equipment; physician bills only the interpretation)
Increased procedural services — unusually complex injection (e.g., severe scarring, abnormal anatomy) requiring significantly more physician work; must be supported by operative note
⚠️ Coding Note: The most critical billing nuance for spasmodic dysphonia is the 64617 + modifier -50 rule: 64617 is a unilateral code — when bilateral thyroarytenoid injections are performed (the standard of care for ADSD), modifier -50 must be appended and the fee is typically adjusted to 150% of the unilateral rate per CMS MPFS. Do NOT also report +95874 (EMG guidance add-on) when billing 64617 — the descriptor for 64617 explicitly states it already includes needle EMG guidance; appending +95874 with 64617 is incorrect and will result in a claim edit. +95874 is reportable only with flexible scope injection codes (e.g., 31573) or other primary chemodenervation codes whose descriptors do NOT include EMG guidance. For ICD-10-CM selection, the AAPC and most payer sources support R49.0 (Dysphonia) as the standard code for spasmodic dysphonia in the outpatient/ENT setting; G24.8 is appropriate when the provider explicitly documents “laryngeal dystonia” — this distinction matters for medical necessity, as some payers require the G24.8dystonia code for botulinum toxin authorization. Always bill the HCPCS J-code (J0585 etc.) for the botulinum toxin drug separately when your facility/practice incurs the medication cost — omitting the drug code is a common revenue loss point. For post-Botox dysphagia coded as R13.12, this is expected as a transient side effect and is separately codeable when documented by the physician as a distinct, evaluated complication.
Crystal's MCW Coder Hub